FDA pans Merck's new pain pill

Apr 13, 2007

The U.S. Food and Drug Administration has rejected Merck's bid to sell the pain medication Arcoxia in the United States.

The New York Times says Arcoxia is a sister to Vioxx, which Merck pulled from the market in 2004 after a study showed it increased the risks of heart attacks and strokes.

Arcoxia, currently sold in 63 countries, caused nearly three times as many heart attacks, strokes and deaths as naproxen, which is sold as Aleve, and is about just as effective at reducing pain in arthritis patients. Patients taking Arcoxia also suffered increased blood pressure, the newspaper said.

"What you're talking about is a potential public health disaster," Dr. David Graham, an FDA safety officer, told the panel.

The company said it was "disappointed" in the FDA's rejection.

"We continue to believe that Arcoxia has the potential to become a valuable treatment option for many Americans suffering from osteoarthritis," Merck Research Laboratories President Peter Kim said in a release.

Merck will continue to sell the drug outside the United States, the newspaper said.

Copyright 2007 by United Press International

Explore further: Combining epilepsy drug, morphine can result in less pain, lower opioid doses

add to favorites email to friend print save as pdf

Related Stories

US judge fines HP $59 mn for bribing Russian officials

5 hours ago

A judge on Thursday ordered US computer giant Hewlett-Packard to pay $58.8 million for bribing Russian government officials to win a big-money contract with the prosecutor general's office in that nation.

Solar storm heads Earth's way after double sun blasts

5 hours ago

Two big explosions on the surface of the sun will cause a moderate to strong geomagnetic storm on Earth in the coming days, possibly disrupting radio and satellite communications, scientists said Thursday.

US threatened Yahoo with huge fine over surveillance

6 hours ago

US authorities threatened to fine Yahoo $250,000 a day if it failed to comply with a secret surveillance program requiring it to hand over user data in the name of national security, court documents showed ...

Microbes evolve faster than ocean can disperse them

6 hours ago

Two Northeastern University researchers and their international colleagues have created an advanced model aimed at exploring the role of neutral evolution in the biogeographic distribution of ocean microbes.

Recommended for you

Vaccine proves effective against deadly Middle East virus

15 hours ago

(Medical Xpress)—A vaccine developed by an international team of scientists led by the University of Pittsburgh School of Medicine successfully protects mice against a contagious and deadly virus spreading across the Middle ...

New study looks at improving vaccine awareness

17 hours ago

The best medical therapies won't do much good if the public abstains from using them. Resistance to life-saving interventions may have a variety of root causes, particularly if the biotechnology involved is new and poorly ...

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

User comments : 0